Zetwerk Files For IPO Via The Confidential Route: Targets Around ₹4,000 Crore Issue

Zetwerk, a manufacturing firm, is preparing to go public and has already taken the first step. It has filed a confidential prospectus with the Securities and Exchange Board of India, although key details are still undisclosed.

The company is expected to list later this year, but what does the entry of this manufacturing startup mean for investors?

How Is Zetwerk’s IPO Shaping Up?

Zetwerk is looking at raising around ₹4,000 crore through its Initial Public Offering (IPO), with a combination of fresh issue and an offer for sale. The firm has appointed Kotak Mahindra, Goldman Sachs, Pantomath Investment Bank, Morgan Stanley, HSBC and JM Financial as merchant bankers for the issue.

Alongside the main IPO, Zetwerk is also planning a pre-IPO round of ₹500 crore with Bharat Value Fund and a group of high-net-worth investors. The pre-IPO round is aimed at strengthening the firm’s balance sheet while also providing an exit opportunity for early investors.

Zetwerk has chosen the confidential route for filing its papers, unlike the regular route, due to which exact details like the issue size, type and use of funds are not publicly available.

SEBI introduced this route in 2022. Companies use it when they prefer to hold back sensitive financial or operational details in the early stages.

How Does Zetwerk Run Its Business?

Zetwerk operates as a tech-led manufacturing platform, linking businesses with a wide supplier network across markets. The firm relies on partner networks for production, instead of building large in-house capacities.

It works across sectors like energy, electronics, aerospace and defence, commodities, capital goods, and precision manufacturing.

So far, it has served over 1,100 customers across 19 countries. On the supply side, it is connected to more than 5,400 vendors across 25 countries, along with a smaller base of owned facilities.

Financially, revenue came in at ₹12,798 crore in FY25, about 11% lower than the ₹14,443 crore reported a year earlier. Losses, however, reduced sharply to ₹371 crore in FY25, from ₹918 crore in FY24.

Also Read - Novo Nordisk Reduces Ozempic, Wegovy Prices In India Amid Generic Competition

What Should Investors Watch Going Ahead?

The company’s inconsistent profitability could be a point of caution for some investors. Given that it is still a startup, the path to profitability and how execution plays out will matter.

There is also a broader backdrop to consider. Ongoing geopolitical tensions have already led some larger companies to hold back or delay their IPO plans.

From an investor standpoint, attention is likely to be on how the issue is structured, the valuation it seeks, and whether the improvement in losses continues.

Sources:

Business Standard

The Economic Times

Money Control